Drug Profile
Research programme: diabetes therapeutics - Ampika
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Ampika
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Diabetes-mellitus in United Kingdom
- 11 Aug 2016 Research programme: diabetes therapeutics - Ampika is available for licensing as of 11 Aug 2016. http://www.ampika.com/
- 11 Aug 2016 Early research in Diabetes mellitus in United Kingdom (unspecified route)